The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Eisai to Kick Off Global PIII for Lenvatinib as First-Line RCC Therapy
October 3, 2016
- Mochida to Solely Distribute Janssen’s Pain Drug Tramcet from January
October 3, 2016
- Teva Pharma Japan Renamed “Teva Takeda Pharma”
October 3, 2016
- Takecab Most Heavily Promoted Drug in August: Anterio
October 3, 2016
- Suzuken’s Harvoni Sales Sag 70% from Peak, Wholesaler Earnings Certain to Take Hit
September 30, 2016
- Daiichi Sankyo, Zymeworks Seal Immuno-Oncology Cross-Licensing Pact
September 30, 2016
- Chugai Licenses Atopic Dermatitis Hopeful to Maruho in Japan, Retains Rights for Hemodialysis Pruritus
September 29, 2016
- Maruho Gets Rights to Astellas’ JAK Inhibitor for Skin Diseases
September 29, 2016
- Pruritus Drug Remitch Filed for Use in Peritoneal Dialysis Patients
September 29, 2016
- Tokyo Startup’s Osteoarthritis Drug Hopeful on Tap for PIb Launch by Year-End
September 28, 2016
- Celgene Poised to Boost Japan Organization as New Launch Nears
September 28, 2016
- Psoriasis Drug Lumicef to Hit Shelves on Sept. 30: Kyowa Kirin
September 28, 2016
- Sawai Files Myrbetriq Generic in US, Its 2nd Product after Livalo Copy
September 28, 2016
- Eisai Seeks Label Expansion for Fycompa to Include Monotherapy
September 28, 2016
- Novel MR Antagonist Enters Japan PIII for Hypertension: Daiichi Sankyo
September 28, 2016
- Otsuka-Lundbeck’s Alzheimer’s Med Idalopirdine Stumbles in PIII
September 27, 2016
- Rexulti OK’ed for Schizophrenia Maintenance Therapy in US
September 27, 2016
- Daiichi Sankyo Seeks RA Indication for Pralia
September 26, 2016
- Takeda, France’s Affilogic Join Hands on CNS Drugs
September 23, 2016
- Takeda Ties Up with India’s Zydus Cadila for Chikungunya Vaccine
September 23, 2016
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…